IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company that develops targeted therapeutics for molecularly defined solid tumor indications. The company's research and development strategy integrates small-molecule drug discovery with translational biomarkers to match specific therapies to patient populations based on genetic signatures. Its pipeline is heavily focused on synthetic lethality and antibody-drug conjugates (ADCs), aiming to selectively kill cancer cells while sparing healthy tissue. Key clinical programs include darovasertib for uveal melanoma, as well as candidates targeting MAT2A, PARG, Pol Theta, and Werner Helicase. IDEAYA collaborates with major pharmaceutical companies to advance its drug candidates through clinical trials and potential commercialization.
